ECONOPRED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ECONOPRED (ECONOPRED).
Prednisolone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vascular permeability.
| Metabolism | Prednisolone is primarily metabolized in the liver via conjugation to glucuronide and sulfate metabolites. CYP3A4 may contribute to minor oxidation pathways. |
| Excretion | Prednisolone is primarily metabolized in the liver; metabolites are excreted renally. Approximately 60-70% of a dose is excreted in urine as metabolites, with less than 10% as unchanged drug. Fecal excretion accounts for 10-15%. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours for prednisolone. However, the biological half-life (duration of adrenal suppression) is 24-36 hours due to intracellular receptor binding and slow dissociation. |
| Protein binding | Prednisolone is approximately 70-80% bound to plasma proteins, primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Apparent volume of distribution (Vd) is approximately 0.5-1 L/kg. This indicates moderate distribution into tissues, with higher concentrations in liver and kidney. |
| Bioavailability | For ophthalmic administration, systemic bioavailability is low (less than 5%) due to limited absorption through the cornea and conjunctiva. Oral prednisolone has ~80% bioavailability, but ECONOPRED is not intended for systemic use. |
| Onset of Action | Ophthalmic solution: Onset of anti-inflammatory effect occurs within 2-4 hours after instillation. Systemic absorption may produce effects within 1-2 hours. |
| Duration of Action | Duration of action for ophthalmic use is typically 4-8 hours per dose; however, adrenal suppression may persist for 24-36 hours after systemic absorption. |
| Molecular Weight | 360.44 |
1 drop in the affected eye(s) every 1-2 hours during the day and every 2 hours at night until clinical response, then reduce frequency to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension, 1% prednisolone acetate equivalent.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific dosage adjustment required for renal impairment; systemic absorption is minimal. |
| Liver impairment | No specific dosage adjustment required for hepatic impairment based on Child-Pugh score; systemic absorption is minimal. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use is not recommended in children for ophthalmic indications due to risk of adrenal suppression and growth retardation. |
| Geriatric use | No specific geriatric dose adjustment; use lowest effective dose and monitor intraocular pressure closely as elderly may have increased risk of corticosteroid-induced glaucoma. |
| 1st trimester | Use only if clearly needed due to risk of cleft palate (first trimester) and potential for adrenal suppression in fetus. Corticosteroids are pregnancy category C. |
| 2nd trimester | Use only if clearly needed; may cause fetal growth restriction and adrenal suppression. Monitor for intrauterine growth restriction. |
| 3rd trimester | Use only if clearly needed; may cause fetal adrenal suppression and neonatal hypoglycemia. Avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for ECONOPRED (ECONOPRED).
| Placental transfer | Prednisolone crosses the placenta, but is metabolized to a less active form by placental 11-beta-hydroxysteroid dehydrogenase type 2. Degree of transfer is approximately 10-15% of maternal serum levels. |
| Breastfeeding | Systemic corticosteroids appear in breast milk in small amounts. Doses up to 40mg daily of prednisolone (equivalent) are unlikely to cause systemic effects in the infant. However, Econopred (prednisolone acetate) is a topical ophthalmic preparation; systemic absorption is minimal, thus breastfeeding is considered safe. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to prednisolone or any componentUntreated bacterial, fungal, viral, or mycobacterial ocular infectionsCorneal epithelial herpes simplex (dendritic keratitis)Fungal diseases of the eye
| Precautions | Prolonged use may lead to ocular side effects including glaucoma, cataract formation, secondary ocular infection, and delayed wound healing., Systemic absorption may occur with topical ophthalmic use, especially in children., Monitor intraocular pressure if used for 10 days or longer., Use with caution in patients with corneal thinning or perforation., May mask or exacerbate infections. |
| Food/Dietary | No known food interactions. Avoid alcohol if concurrent systemic corticosteroids are used. |
Loading safety data…
| Lactation Rating | L2 (Safer) - For ophthalmic use, minimal systemic absorption; compatible with breastfeeding. |
| Teratogenic Risk | Corticosteroids are generally considered low risk in pregnancy. First trimester: No significant association with major malformations in epidemiologic studies, though a small increased risk of oral clefts has been reported with first-trimester exposure (absolute risk ~1 per 1000). Second and third trimesters: Increased risk of fetal growth restriction, preterm birth, and maternal glucose intolerance with chronic use. Systemic absorption from ophthalmic ECONOPRED is minimal but may accumulate with frequent dosing. |
| Fetal Monitoring | Monitor maternal blood glucose in diabetic patients or those with gestational diabetes. In prolonged therapy, assess fetal growth via ultrasound to detect growth restriction. No specific fetal monitoring required for short-term use. |
| Fertility Effects | No specific data on fertility effects from ophthalmic prednisolone. Systemic corticosteroids may disrupt menstrual cycles or reduce fertility, but topical application is unlikely to have significant systemic effects. |
| Clinical Pearls | Econopred (prednisolone acetate ophthalmic suspension) is a corticosteroid for ocular inflammation. Shake vigorously before use. Monitor intraocular pressure (IOP) regularly; steroid-induced glaucoma can occur. Avoid prolonged use to prevent cataracts and secondary infections. Use with caution in patients with corneal thinning or prior herpetic keratitis. |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · Report any eye pain, vision changes, or increased redness immediately. · Do not discontinue abruptly; follow tapering instructions if prescribed. |